Nature Communications (Mar 2024)

Expression of USP25 associates with fibrosis, inflammation and metabolism changes in IgG4-related disease

  • Panpan Jiang,
  • Yukai Jing,
  • Siyu Zhao,
  • Caini Lan,
  • Lu Yang,
  • Xin Dai,
  • Li Luo,
  • Shaozhe Cai,
  • Yingzi Zhu,
  • Heather Miller,
  • Juan Lai,
  • Xin Zhang,
  • Xiaochao Zhao,
  • Yonggui Wu,
  • Jingzhi Yang,
  • Wen Zhang,
  • Fei Guan,
  • Bo Zhong,
  • Hisanori Umehara,
  • Jiahui Lei,
  • Lingli Dong,
  • Chaohong Liu

DOI
https://doi.org/10.1038/s41467-024-45977-7
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 18

Abstract

Read online

Abstract IgG4-related disease (IgG4-RD) has complex clinical manifestations ranging from fibrosis and inflammation to deregulated metabolism. The molecular mechanisms underpinning these phenotypes are unclear. In this study, by using IgG4-RD patient peripheral blood mononuclear cells (PBMCs), IgG4-RD cell lines and Usp25 knockout mice, we show that ubiquitin-specific protease 25 (USP25) engages in multiple pathways to regulate fibrotic and inflammatory pathways that are characteristic to IgG4-RD. Reduced USP25 expression in IgG4-RD leads to increased SMAD3 activation, which contributes to fibrosis and induces inflammation through the IL-1β inflammatory axis. Mechanistically, USP25 prevents ubiquitination of RAC1, thus, downregulation of USP25 leads to ubiquitination and degradation of RAC1. Decreased RAC1 levels result in reduced aldolase A release from the actin cytoskeleton, which then lowers glycolysis. The expression of LYN, a component of the B cell receptor signalosome is also reduced in USP25-deficient B cells, which might result in B cell activation deficiency. Altogether, our results indicate a potential anti-inflammatory and anti-fibrotic role for USP25 and make USP25 a promising diagnostic marker and potential therapeutic target in IgG4-RD.